Life Expectancy with High Lipoprotein(a): What Can You Do to Offset Your Risk?

Lipoprotein(a), or Lp(a), is increasingly recognized as one of the most important hereditary risk factors for cardiovascular disease. While many people are familiar with LDL or HDL cholesterol, Lp(a) has historically flown under the radar. That is changing. More physicians are ordering tests for it, new treatments are emerging, and researchers are publishing large-scale studies showing just how significant this molecule can be.

High Lp(a) levels are almost entirely genetic, meaning they are present from birth and remain stable throughout life. Unlike other cholesterol particles, Lp(a) is not meaningfully affected by diet, exercise, or most lifestyle interventions. This makes it a unique, and in some cases frustrating, part of cardiovascular risk management. Understanding how elevated Lp(a) impacts long-term health, and what can be done to reduce that risk, is essential for patients and clinicians alike.

Instalab Research

The Structure and Function of Lp(a)

Lipoprotein(a) resembles LDL cholesterol in structure, but with one critical difference: it includes a second protein, apolipoprotein(a), which gives it additional adhesive and inflammatory properties. This structural feature allows Lp(a) to both promote plaque buildup in arteries and contribute to blood clotting. These mechanisms are central to why elevated Lp(a) raises the risk of events like heart attacks and strokes.

Because Lp(a) levels are genetically determined, a single blood test is usually sufficient to assess a person’s lifelong exposure. Studies show that approximately one in five people worldwide have elevated Lp(a), though prevalence can vary by ethnicity. Unfortunately, routine cholesterol panels do not typically measure Lp(a), meaning many at-risk individuals remain unaware.

Lp(a) and Life Expectancy: What the Evidence Shows

The most significant impact of high Lp(a) is its role in increasing cardiovascular risk. Multiple large-scale studies and genetic analyses have established that elevated Lp(a) is associated with higher rates of coronary heart disease, aortic valve stenosis, and ischemic stroke. These risks are often independent of, and additive to, other common factors like high LDL cholesterol, smoking, or diabetes.

One major population study found that individuals in the top percentile of Lp(a) levels had a 15 to 20 percent higher risk of all-cause mortality compared to those with low levels. Another genetic study showed that people with inherited high Lp(a) had a 50 percent greater risk of coronary artery disease. More recent modeling studies have suggested that very high levels of Lp(a), particularly over 180 mg/dL, may reduce life expectancy by up to five years, depending on the presence of other risk factors.

This is not merely theoretical. People with elevated Lp(a) are more likely to experience cardiovascular events earlier in life and may require interventions such as stenting or valve replacement sooner than their peers. The cumulative lifetime exposure to high Lp(a) plays a critical role in this increased risk.

A Broader Range of Diseases

The impact of Lp(a) is not limited to coronary artery disease. One of the strongest and most consistent associations in the literature is between high Lp(a) and aortic stenosis, a condition where the heart’s main valve becomes narrowed and stiff. Over time, this can lead to heart failure and may require valve replacement. Elevated Lp(a) is now considered a causal factor in the development of this condition.

Lp(a) is also linked to stroke, especially ischemic stroke in younger individuals. While not every person with high Lp(a) will experience these outcomes, the evidence suggests that elevated levels significantly increase the likelihood of cardiovascular complications over the course of a lifetime.

What Treatments Are Available?

Standard cholesterol-lowering therapies like statins are effective in reducing LDL cholesterol but do little to lower Lp(a). In some cases, statins may even cause a modest increase in Lp(a) levels, though the overall benefit in reducing cardiovascular risk still makes them an essential part of treatment.

PCSK9 inhibitors, which are injectable medications used primarily to lower LDL cholesterol, have shown modest success in reducing Lp(a) by about 20 to 30 percent. Clinical trials suggest this reduction may translate into lower cardiovascular risk, although the drugs are not approved specifically for Lp(a) management.

The most promising development is the advent of antisense therapies that directly target the genetic instructions for making apolipoprotein(a). Early-phase trials of these therapies have demonstrated up to 80 percent reductions in Lp(a) levels. Ongoing studies are now evaluating whether this dramatic lowering results in fewer heart attacks and strokes. If proven effective, these treatments could become the first targeted therapy for elevated Lp(a).

Risk Reduction Without Direct Lp(a) Lowering

Until targeted therapies become widely available, managing other risk factors becomes especially important for people with high Lp(a). This includes maintaining healthy blood pressure, controlling blood sugar, stopping smoking, and keeping LDL cholesterol as low as possible. While lifestyle changes may not reduce Lp(a) itself, they play a major role in mitigating overall cardiovascular risk.

For many patients, a combination of medications and lifestyle changes can bring total cardiovascular risk down to acceptable levels, even if Lp(a) remains elevated. In this context, a high Lp(a) level should be seen as one part of a larger risk profile, not a deterministic prediction of future disease.

The Importance of Testing

Despite the strong evidence linking Lp(a) to reduced life expectancy, most people have never had their levels tested. Because Lp(a) is inherited and stable over time, a single test is sufficient for most patients. Testing is especially important for individuals with a family history of early heart disease or stroke, or those who have experienced cardiovascular events despite normal cholesterol levels.

With greater awareness, more clinicians are beginning to include Lp(a) testing in routine cardiovascular risk assessments. This can help identify patients who might benefit from more aggressive prevention strategies or novel therapies as they become available.

A New Era in Managing High Lipoprotein(a)

High Lp(a) levels are one of the most significant genetic risk factors for cardiovascular disease. For those with very elevated levels, the impact on life expectancy can be meaningful, especially in the presence of other risk factors. However, the outlook is far from bleak. Early identification, careful management, and emerging treatments are changing the landscape for patients with high Lp(a).

What was once an overlooked molecule is now at the forefront of cardiovascular prevention. With the right strategy, patients with elevated Lp(a) can take meaningful steps to protect their heart health and improve their long-term outcomes.

References

Clarke, R., Peden, J., Hopewell, J., Kyriakou, T., Goel, A., Heath, S., Parish, S., Barlera, S., Franzosi, M., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F., Lathrop, M., Gigante, B., Leander, K., De Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M. (2009). Genetic variants associated with Lp(a) lipoprotein level and coronary disease.. The New England journal of medicine, 361 26, 2518-28 . https://doi.org/10.1056/NEJMoa0902604.
Waldeyer, C., Makarova, N., Zeller, T., Schnabel, R., Brunner, F., Jørgensen, T., Linneberg, A., Niiranen, T., Salomaa, V., Jousilahti, P., Yarnell, J., Ferrario, M., Veronesi, G., Brambilla, P., Signorini, S., Iacoviello, L., Costanzo, S., Giampaoli, S., Palmieri, L., Meisinger, C., Thorand, B., Kee, F., Koenig, W., Ojeda, F., Kontto, J., Landmesser, U., Kuulasmaa, K., & Blankenberg, S. (2017). Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. European Heart Journal, 38, 2490 - 2498. https://doi.org/10.1093/eurheartj/ehx166.
Kamstrup, P., Tybjærg‐Hansen, A., & Nordestgaard, B. (2014). Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.. Journal of the American College of Cardiology, 63 5, 470-7 . https://doi.org/10.1016/j.jacc.2013.09.038.
Rigal, M., Ruidavets, J., Viguier, A., Petit, R., Perret, B., Ferrieres, J., & Larrue, V. (2007). Lipoprotein (a) and risk of ischemic stroke in young adults. Journal of the Neurological Sciences, 252, 39-44. https://doi.org/10.1016/j.jns.2006.10.004.
O’Donoghue, M., Fazio, S., Giugliano, R., Stroes, E., Kanevsky, E., Gouni-Berthold, I., Im, K., Pineda, A., Wasserman, S., Češka, R., Ezhov, M., Jukema, J., Jensen, H., Tokgözoğlu, L., Mach, F., Huber, K., Sever, P., Keech, A., Pedersen, T., & Sabatine, M. (2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation, 139, 1483–1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.
Viney, N., Capelleveen, J., Geary, R., Xia, S., Tami, J., Yu, R., Marcovina, S., Hughes, S., Graham, M., Crooke, R., Crooke, S., Witztum, J., Stroes, E., & Tsimikas, S. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet, 388, 2239-2253. https://doi.org/10.1016/S0140-6736(16)31009-1.